Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 2 of 2 entries
View as:
Phase: N/A
Priority: Normal
Start: 01/10/18
End: 07/29/22
Due: 07/29/23
Phase: N/A
Priority: Normal
Start: 09/26/17
End: 08/25/21
Due: 08/25/22
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Pembrolizumab + Poly-ICLC in MRP Colon Cancer | NCT02834052 | Asha Nayak | user2@example.com | None | 2018-01-10 | 2022-07-29 | 2023-07-29 | - | - | 2025-07-14 |
| Pembrolizumab + Idelalisib for Lung Cancer Study | NCT03257722 | Asha Nayak | user2@example.com | None | 2017-09-26 | 2021-08-25 | 2022-08-25 | - | - | 2025-07-14 |